• January 18, 2021

Insomnia Pipeline Review, H2 2020 - Therapeutic Assessment of 29 Companies & Respective Drug Profiles - ResearchAndMarkets.com - Odessa American: Business

e-Edition Subscribe

Insomnia Pipeline Review, H2 2020 - Therapeutic Assessment of 29 Companies & Respective Drug Profiles - ResearchAndMarkets.com

Font Size:
Default font size
Larger font size

Posted: Thursday, December 31, 2020 7:48 am

DUBLIN--(BUSINESS WIRE)--Dec 31, 2020--

The "Insomnia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Insomnia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 9, 7, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:


Insomnia - Overview

Insomnia - Therapeutics Development

Insomnia - Therapeutics Assessment

Insomnia - Companies Involved in Therapeutics Development

Insomnia - Drug Profiles

Insomnia - Dormant Projects

Insomnia - Discontinued Products

Insomnia - Product Development Milestones


Companies Mentioned

  • Amherst Pharmaceuticals LLC
  • Artelo Biosciences Inc
  • Biohemp International Inc
  • Cannabis Science Inc
  • Cennerv Pharma (S) Pte Ltd
  • Ci Therapeutics
  • Eisai Co Ltd
  • EUSOL Biotech Co Ltd
  • Evotec SE
  • Grupo Ferrer Internacional SA
  • Guangdong East Sunshine Pharmaceutical Co Ltd
  • Idorsia Pharmaceutical Ltd
  • Imbrium Therapeutics LP
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Linnet BioPharmaceuticals Inc
  • M et P Pharma AG
  • NB Health Laboratory Co Ltd
  • Neurim Pharmaceuticals Ltd
  • NeuroFix Therapeutics LLC
  • Overseas Pharmaceuticals Ltd
  • Renascence Therapeutics Ltd
  • Reviva Pharmaceuticals Inc
  • Sage Therapeutics Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Tetranov International Inc
  • Tritech Biopharmaceuticals Co Ltd
  • Yangtze River Pharmaceutical Group
  • Zelira Therapeutics Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jmjzst

View source version on businesswire.com:https://www.businesswire.com/news/home/20201231005146/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/31/2020 08:48 AM/DISC: 12/31/2020 08:48 AM


© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Humidity: 56%
Winds: S at 8mph
Feels Like: 34°

Your Extended Forecast


High 59°/Low 36°
Mainly clear. Lows overnight in the mid 30s.


High 69°/Low 36°
Abundant sunshine. Highs in the upper 60s and lows in the mid 30s.


High 44°/Low 36°
Mostly cloudy. Highs in the mid 40s and lows in the mid 30s.


High 50°/Low 41°
Mostly cloudy. Highs in the low 50s and lows in the low 40s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.